A combination of a CTLA-4-blocking antibody and a GVAX cancer vaccine may be more effective in treating melanoma and advanced ovarian cancer than either treatment on its own, according to a U.S. study. Researchers reported that none of the patients who received the combination therapy experienced severe adverse reactions, while some found that their tumors had shrunk or stabilized.

Full Story:

Related Summaries